Tips For Viral Vector Production

Learn about how meticulous purification optimization can maximize recovery and impurity removal by leveraging scalable downstream technologies to meet regulatory and process economy requirements.

2024 CIO Survey Reveals IT Budgets, AI Priorities For Life Sciences Companies

Clarkston Consulting conducted its third annual Chief Information Officer (CIO) Survey to understand IT budgets of life sciences companies, how AI priorities fit into those budgets, and more.

Top Challenges In Recombinant Protein Purification Process Development

Get insights from process developers working with recombinant proteins that cannot be purified with affinity chromatography.

Three Key Considerations For Optimizing Process Development

When it comes to process development, timing, technology, and partners all merit careful consideration. Explore expert insights into these three crucial factors.

Navigating Cell Therapy Process Development

Explore the main challenges and considerations inherent in cell therapy process development.

Formulation Process And Analytical Development Capabilities

Explore process and analytical development capabilities that can help you advance your formulation to GMP Manufacturing.

Advancing A LNP Formulation To Clinical And Commercial Manufacturing

Lipid selection impacts the final LNP drug product and the LNP process. Review critical quality considerations for lipids and the process requirements for successful commercial-scale manufacturing.

Process Development With “The End In Mind” For Startups

We encounter the term “the end in mind” in product development frequently, but many are unsure what it really means and when it matters. This article sheds light.

Building Biopharma Resilience In Developing Gene Therapies

Learn about the opportunities and challenges surrounding gene therapies, the importance of collaboration between biopharma startups and academia, difficulties with the talent pipeline, and more.

Biopharmaceuticals: State Of The Industry

How are government policies, talent pools, and supply chain constraints affecting the state of the industry? Learn about the biopharma industry’s biggest strengths, greatest challenges, and much more.

Biopharma Resilience: Mass Immunization Programs

Explore the challenges involved with mass immunization programs, what role government can play in facilitating vaccination programs, how technology is transforming the biopharma industry, and more.

2024 LIMS Trends

The laboratory information management system (LIMS) landscape in 2024 is a dynamic one, driven by accelerating advancements in technology and evolving industry needs. This article shares the four key trends.

The Power Couple: CRISPR And Oligonucelotides

Drug design using CRISPR depends on long guide RNA (gRNA) sequences. Find out how this love match between long oligos and CRISPR works.

Five Essentials For Accurate Oligonucleotide Chemistry

Explore five key areas in oligonucleotide chemistry where improvements will have a huge influence on your synthesis quality.

A New Reality In Life Sciences

Gain insight from this author's experience with virtual reality (VR) and the specific benefits of VR in scientific contexts.

Big Risks Yield Great Rewards In Cell Therapy

George White, Cytiva’s GM of Product Management for Cell and Gene Therapy, provides insight into the latest developments and strategies in cell therapy and where this dynamic field is headed.

Finding The Talent To Fuel Biopharma Breakthroughs

Explore findings from research into talent pool resilience in the biopharmaceutical industry that incorporate survey insights as well as external data to ensure a more accurate overview.

Impact Of Glycosylation On The Effector Functions Of Monoclonal Antibodies

In an example using rituximab and its biosimilars, explore the significance of minor differences of glycosylation in antibodies and its impact on their properties and functionality.

Impact Of Immunogenicity On Efficacy And Safety Of Biosimilars

The presence of anti-drug antibodies (ADAs) can affect the effectiveness and safety of biologic drugs. Read why regulatory agencies emphasize the need for extensive immunogenicity evaluation in biosimilar development.

Metabolite And Nutrient Analysis As Crucial Components For Optimal Upstream Process

Discover how insights into cell metabolism can further enable the development of efficient cell culture processes through tailored nutrient supplementation and monitoring.

Development And Regulation Of Veterinary Monoclonals

Although veterinary mAbs have achieved commercial success, ongoing discussions and clinical developments surrounding them are expected to outline a clear regulatory pathway in the near future.

The Latest Trends In The Prevention And Treatment Of Cervical Cancer

Unearth what immune checkpoint inhibitors are showing promise in treating cervical cancer and how advancements in these treatments paired with additional prevention strategies are improving patient outcomes.

Novel Approaches For Obtaining High-productivity Clones

Let's dig into cell line selection approaches, transposons to increase copy number for the gene of interest, and targeted integration to rapidly obtain high-productivity clones.

Lowering The Lipids Barrier: The Key To Accelerating RNA-LNP Drug Development

Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.

Getting CMC Right For Emerging Technologies

Establishing a chemistry, manufacturing, and controls strategy that proves a clinical program is tightly controlled and can address risk is critical to avoiding the pitfalls that stall many promising therapeutics.

Pacesetters Are Product Innovators Who Embrace Digital Process Enhancement

The Josh Bersin Company recently underwent research examining pharma/biotech “pacesetters” in the field. We caught up with Jordan Schmitting, senior research analyst at The Josh Bersin Company, to discuss the trends illuminated by the research.

Following The Science To Develop Best-In-Class Cancer Drugs

As innovative cancer therapeutics continue to enter the clinical trial pipeline, some developers are shifting their focus toward developing drugs that are safe and efficacious with minimal toxicity.

A Lean, Agile Business Model To Deliver High-Quality Oncologic Treatments

No two journeys through the drug pipeline are the same; the ability to leverage a variety of approaches for different products is what sets one lean biotech company apart.

A Tale Of Two Brothers: The Abpro Founders

By founding their latest venture, Abpro, Ian and Eugene Chan are using their synergistic skillsets in business and medicine to rapidly generate antibodies that treat cancer and autoimmune diseases.

Welcoming The “Era Of ADCs”

Dr. Loretta Itri sat down to explore the promise of TRODELVY®️ and other antibody-drug conjugates as transformative treatments for a range of malignancies and intractable diseases.